Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash from Operations (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Cash from Operations for 3 consecutive years, with 7309000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 2.79% to 7309000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 32709000.0, a 8.3% decrease, with the full-year FY2024 number at 32834000.0, down 55.38% from a year prior.
  • Cash from Operations was 7309000.0 for Q3 2025 at Mereo BioPharma, up from 7651000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 2659000.0 in Q3 2023 to a low of 9420000.0 in Q4 2024.
  • A 3-year average of 7023181.82 and a median of 7754000.0 in 2023 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 13.59% in 2024; the steepest drop was 382.78% in 2024.
  • Mereo BioPharma's Cash from Operations stood at 6789000.0 in 2023, then crashed by 38.75% to 9420000.0 in 2024, then rose by 22.41% to 7309000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Cash from Operations are 7309000.0 (Q3 2025), 7651000.0 (Q2 2025), and 8329000.0 (Q1 2025).